Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $2.5 million.

  • Ascendis Pharma A's Free Cash Flow rose 10411.73% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$114.0 million, marking a year-over-year increase of 5967.11%. This contributed to the annual value of -$331.4 million for FY2024, which is 3374.81% up from last year.
  • Ascendis Pharma A's Free Cash Flow amounted to $2.5 million in Q3 2025, which was up 10411.73% from -$8.3 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Free Cash Flow registered a high of $2.5 million during Q3 2025, and its lowest value of -$192.1 million during Q4 2021.
  • In the last 5 years, Ascendis Pharma A's Free Cash Flow had a median value of -$101.7 million in 2021 and averaged -$99.2 million.
  • Per our database at Business Quant, Ascendis Pharma A's Free Cash Flow plummeted by 13456.6% in 2021 and then skyrocketed by 10411.73% in 2025.
  • Over the past 5 years, Ascendis Pharma A's Free Cash Flow (Quarter) stood at -$192.1 million in 2021, then rose by 26.76% to -$140.7 million in 2022, then soared by 67.47% to -$45.8 million in 2023, then crashed by 103.56% to -$93.2 million in 2024, then soared by 102.7% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, -$8.3 million for Q2 2025, and -$15.1 million during Q1 2025.